Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation?

Newton RU, Taaffe DR, Spry N, Cormie P, Chambers SK, Gardiner RA, Shum DH, Joseph D, Galvão DA.

BMC Cancer. 2012 Sep 26;12:432. doi: 10.1186/1471-2407-12-432.

2.

Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review.

Gardner JR, Livingston PM, Fraser SF.

J Clin Oncol. 2014 Feb 1;32(4):335-46. doi: 10.1200/JCO.2013.49.5523. Epub 2013 Dec 16. Review.

PMID:
24344218
3.

Background to and management of treatment-related bone loss in prostate cancer.

Berruti A, Tucci M, Terrone C, Gorzegno G, Scarpa RM, Angeli A, Dogliotti L.

Drugs Aging. 2002;19(12):899-910. Review.

PMID:
12495366
4.

Bone health in men receiving androgen deprivation therapy for prostate cancer.

Eastham JA.

J Urol. 2007 Jan;177(1):17-24. Review.

PMID:
17161994
5.

Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.

Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD.

Med J Aust. 2011 Mar 21;194(6):301-6. Review.

PMID:
21426285
6.

Androgen deprivation therapy: evidence-based management of side effects.

Ahmadi H, Daneshmand S.

BJU Int. 2013 Apr;111(4):543-8. doi: 10.1111/j.1464-410X.2012.11774.x. Epub 2013 Jan 25. Review.

7.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
8.

Complications of androgen deprivation therapy in prostate cancer.

Schwandt A, Garcia JA.

Curr Opin Urol. 2009 May;19(3):322-6. doi: 10.1097/MOU.0b013e32832a082c. Review.

PMID:
19318949
9.

Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.

Galvão DA, Taaffe DR, Spry N, Newton RU.

Prostate Cancer Prostatic Dis. 2007;10(4):340-6. Epub 2007 May 8. Review.

PMID:
17486110
10.

Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.

Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ.

Pharmacotherapy. 2008 Dec;28(12):1511-22. doi: 10.1592/phco.28.12.1511. Review.

PMID:
19025432
11.

Contemporary role of androgen deprivation therapy for prostate cancer.

Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schröder FH, Sternberg CN, Studer UE.

Eur Urol. 2012 Jan;61(1):11-25. doi: 10.1016/j.eururo.2011.08.026. Epub 2011 Aug 19. Review.

12.

Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.

Ross RW, Small EJ.

J Urol. 2002 May;167(5):1952-6. Review.

PMID:
11956415
13.

Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.

Schulman C, Irani J, Aapro M.

BJU Int. 2012 Jun;109 Suppl 6:13-21. doi: 10.1111/j.1464-410X.2012.11216.x. Review.

14.

Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy.

Storer TW, Miciek R, Travison TG.

Asian J Androl. 2012 Mar;14(2):204-21. doi: 10.1038/aja.2011.104. Epub 2012 Feb 27. Review.

15.

Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure.

Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU.

Prostate Cancer Prostatic Dis. 2009;12(3):233-40. doi: 10.1038/pcan.2009.12. Epub 2009 Jun 2. Review.

PMID:
19488067
16.

The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.

Smith MR.

Oncology (Williston Park). 2004 May;18(5 Suppl 3):21-5. Review.

PMID:
15202584
17.

[Oncoforum in urology and review of the literature].

Hennequin C.

Cancer Radiother. 2008 Sep;12 Spec No 2:1-8. doi: 10.1016/S1278-3218(08)73947-7. Review. French.

PMID:
18823869
18.

Exercise in prevention and management of cancer.

Newton RU, Galvão DA.

Curr Treat Options Oncol. 2008 Jun;9(2-3):135-46. doi: 10.1007/s11864-008-0065-1. Epub 2008 Aug 13. Review.

PMID:
18704691
19.

Medical therapy of prostate cancer. A review.

Roscigno M, Sangalli M, Mazzoccoli B, Scattoni V, Da Pozzo L, Rigatti P.

Minerva Urol Nefrol. 2005 Jun;57(2):71-84. Review.

PMID:
15951731
20.

Metabolic complications of androgen deprivation therapy for prostate cancer.

Saylor PJ, Smith MR.

J Urol. 2009 May;181(5):1998-2006; discussion 2007-8. doi: 10.1016/j.juro.2009.01.047. Epub 2009 Mar 14. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk